Chrysalis

Chrysalis is a SAMHSA-registered addiction-treatment facility in Eureka, MT. The facility offers specific levels of care: Inpatient, Dual Dx. This page frames the questions that matter most when evaluating a specific program — the ones that separate useful candidates from marginal ones.

Care levels at Chrysalis

The facility's documented care levels are The facility offers specific levels of care: Inpatient, Dual Dx. — each of which is appropriate for specific clinical presentations. Matching the level to the specific clinical need is the pre-admission work. ASAM Criteria 4e is the benchmark framework for matching patients to appropriate intensity. Most major payer medical-necessity documents reference it. An outside ASAM-aligned assessment, prior to admission, is the protection against misplacement.

Insurance and payment

Chrysalis operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. The operational prerequisite is written documentation: in-network status for your specific plan product, deductible accumulation, coinsurance rate, prior-authorization status. Admissions without these four documented carry material risk of post-admission financial disagreement.

Specialty programming

The facility's documented specialty programming includes: Members of military families, Clients with co-occurring mental and substance use disorders, Clients who have experienced trauma. Specialty designations benefit from specific follow-up: programming hours per week, credentialed staff profile, integrated assessment protocols. Dual-diagnosis as a marketing category differs from operational specialty infrastructure.

Before you call

The operational due diligence on Chrysalis comes down to three documents: ASAM-aligned level-of-care documentation matching independent clinical assessment, written Verification of Benefits for your specific plan product, written MAT policy. If the clinical situation involves opioid use disorder, confirm explicitly whether Chrysalis offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.